Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 20/20 | 0.67 |
| ▸ | MMP3 | P08254 | 19/20 | 0.67 |
| ▸ | MMP2 | P08253 | 18/20 | 0.67 |
| ▸ | MMP1 | P03956 | 16/20 | 0.65 |
| ▸ | MMP7 | P09237 | 14/20 | 0.65 |
| ▸ | MMP9 | P14780 | 7/20 | 0.63 |
| ▸ | MMP8 | P22894 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256578 | 0.91 | MMP13 (0.81) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL6291093 | 0.86 | MMP13 (0.66) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL6290454 | 0.86 | MMP3 (0.83) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7449727 | 0.85 | MMP3 (0.64) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7452602 | 0.84 | MMP13 (0.74) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7082867 | 0.81 | MMP13 (0.84) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7081118 | 0.81 | MMP13 (0.64) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7238128 | 0.81 | MMP13 (0.67) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7082386 | 0.81 | MMP13 (1.00) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL6289713 | 0.79 | MMP13 (0.86) | MMP13MMP3MMP2MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171400-A1 | Heterocyclic side chain containing metalloprotease inhibitors | PROCTER & GAMBLE COMPANY, THE | 2003-09-11 | — | — | US | disclosed |
| EP-1265863-A1 | HETEROCYCLIC SIDE CHAIN CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001070690-A1 | HETEROCYCLIC SIDE CHAIN CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171400-A1 | Heterocyclic side chain containing metalloprotease inhibitors | SERPINB1, ADAM17, TMPRSS15 | MMP13 70/4885MMP3 14/4885MMP2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.